Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2007-03-29
2009-12-22
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S239100, C424S247100, C424S810000
Reexamination Certificate
active
07635484
ABSTRACT:
The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.
REFERENCES:
patent: 4551435 (1985-11-01), Liberti et al.
patent: 4643718 (1987-02-01), Marten
patent: 5668255 (1997-09-01), Murphy
patent: 6048529 (2000-04-01), Atassi et al.
patent: 6667145 (2003-12-01), Nishi et al.
patent: 6667158 (2003-12-01), Bavari et al.
patent: 6676622 (2004-01-01), Strahilevitz
patent: 6776990 (2004-08-01), Sachs et al.
patent: 6843998 (2005-01-01), Steward et al.
patent: 7214787 (2007-05-01), Smith et al.
patent: 7276473 (2007-10-01), Sachs et al.
patent: 7341843 (2008-03-01), Atassi
patent: 7462699 (2008-12-01), Atassi
patent: 7531179 (2009-05-01), Atassi
patent: 2001/0018049 (2001-08-01), Sachs et al.
patent: 2002/0155114 (2002-10-01), Marks et al.
patent: 2002/0197278 (2002-12-01), Allison
patent: 2003/0009025 (2003-01-01), Smith et al.
patent: 2003/0147895 (2003-08-01), Shone et al.
patent: 2003/0185850 (2003-10-01), Dertzbaugh
patent: 2004/0101534 (2004-05-01), Diamond
patent: 2004/0110284 (2004-06-01), Bavari et al.
patent: 2004/0175385 (2004-09-01), Marks et al.
patent: 2004/0176299 (2004-09-01), Sachs et al.
patent: 2004/0191887 (2004-09-01), Chapman et al.
patent: 2004/0248257 (2004-12-01), Kaye et al.
patent: 2004/0265935 (2004-12-01), Atassi
patent: 2005/0095251 (2005-05-01), Steward et al.
patent: 2005/0106182 (2005-05-01), Li et al.
patent: 2005/0244435 (2005-11-01), Shone et al.
patent: 2007/0037257 (2007-02-01), Smith et al.
patent: 2007/0048335 (2007-03-01), Gil et al.
patent: 94/21684 (1994-09-01), None
patent: 2005/014798 (2005-02-01), None
patent: 2005/030119 (2005-04-01), None
Krieglstein, Kerstin G et al, Journal of Protein Chemistry, vol. 13(1), 1994, pp. 49-57; Covalent Structure of Botulinum Neurotoxin Type A: Location of Sulfhydryl Groups and Disulfide Bridges and Identification of C-termini of Light and Heavy Chains.
Dertzbaugh, Mark T et al, (1996) Vaccine, vol. 14(16), pp. 1538-1544, Mapping of protective and cross-reactive domains of the type a neurotoxin of Clostridium botulinum.
Bavari, S et al, Vaccine, vol. 16(19), pp. 1850-1856, 1998, pp. 1850-1856.
Montal, MS e tal, FEBS Lett. 1992, Nov. 16, vol. 31(3), pp. 12-18, abstract only.
Kubota, Toru et al, Applied and Environmental Microbiology, Apr. 1997, pp. 1214-1218, vol. 63(4), Epitope regions in the Heavy Chain of Clostridium botulinum Type E Neurotoxin Recognized by Monoclonal Antibodies.
Lebeda, Frank J. et al, Journal of Protein Chemistry, vol. 16(6), 1997, pp. 607-618, Predicint differential antigen-antibody contact regions based on solvent accessibility.
Atassi, M. Zouhair, Scientific and Therapeutic Agents of Botulinum toxin 2002, Chapter 38, pp. 385-408, Immune recognition and Cross Reactivity of Botulinum Neurotoxins.
Amersdorfer et al., “Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries,”Vaccine20:1640-1648(2002).
Amersdorfer et al., “Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries,”Infect. Immun65:3743-3752 (1997).
Aoki, “Pharmacology and immunology of botulinum toxin serotypes,”J. Neurol. 248 Suppl. 1:3-10(2001).
Atassi and Dolimbek, “Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the continuous antigenic regions of the H-chain of botulinum neurotoxin A,”ProteinJ. 23:39-52 (2004).
Atassi and Oshima, “Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins”Crit. Revs. Immunol, 19:219-260 (1999).
Atassi and Smith, “A proposal for the nomenclature of antigenic sites in peptides and proteins,”Immunochemistry15:609-610 (1978).
Kozaki et al., “Development of antitoxin with each of two complementary fragments ofClostridium botulinumtype B derivative toxin,”Infection and Immunity18:761-766 (1977).
Kozaki et al, “Immunological characterization of Papain-induced fragments ofClostridium botulinumtype A neurotoxin and interaction of the fragments with brain synaptosomes ”Infection and Immunity57:2634-2639 (1989).
Kozaki et al., “The use of monoclonal antibodies to analyze the structure ofClostridium botulinumtype E derivative toxin,”Infection and Immunity52:786-791 (1986).
Krieglstein, Kerstin G. et al, Journal of protein Chemistry, vol. 13(1), pp. 49-57, 1994.
Kubota et al., “Epitope regions in the heavy chain ofClostridium bolulinumtype E neurotoxin recognized by monoclonal antibodies,”Applied&Environmental Microbiol. 63:1214-1218 (1997).
Lacy et al, “Crystal structure of botulinum neurotoxin type A and implications for toxicity,”Nat. Struct. Biol. 5:898-902 (1998).
Lacy, D. B. et al, “Sequence homology and structural analysis of the Clostridial neurotoxins”, Journal of Molecular Biology, vol. 291, 1999, pp. 1091-1104.
LaPenotiere et al., “Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen,”Toxicon33:1383-1386(1995).
Lebeda, Frank J. et al, “Predicting Differential antigen-antibody contact regions based on solvent accessibility”, Journal of Protein Chemistry, vol. 16(6), 1997, pp. 607-618.
Atassi et al., “Cross-reaction of mouse antibodies against Tetanus neurotoxin with Botulinum neurotoxins A and B,”International Conference 2002, Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Hannover, Germany, Jun. 8-12, Abstract R12 (2002).
Atassi et al., “Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor,”Proc. Natl. Acad. Sci. USA88:3613-3617 (1991).
Atassi et al., “Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species,”J. Prot. Chem. 15:691-700(1996).
Atassi, “Immune recognition and cross-reactivity of botulinum neurotoxins,” inScientific and Therapeutic Aspects of Botulinum Toxins(edited by Brin et al.), pp. 385-408, Lippincott Williams and Wilkins, Philadelphia, PA (2002).
Bavari et al., “Identifying the principal protective antigenic determinants of type A botulinum neurotoxin,”Vaccine16:1850-1856 (1998).
Beecher, DJ et al, J. Protein Chemistry, vol. 16(7), pp. 701-712, 1997.
Byrne, MP et al, vol. 82, 2000, “Development of vaccines for prevention of botulism”, pp. 955-966.
Cenci Di Bello et al., “Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes,”Eur. J. Biochem. 219:161-169(1994).
Chen et al ., “Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms,” Infect. Immun. 65:1626-1630 (1997).
Clayton and Middlebrook, “Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype a,”Vaccine18:1855-1862 (2000).
Clayton et al., “Protective vaccination with a recombinant fragment ofClostridium botulinum, neurotoxin serotype A expressed from a synthetic gene inEscherichia coli,”Infect. Immun. 63:2738-2742 (1995).
Dertzbaugh and West, “Mapping of protective and cross-reactive domains of the type A neurotoxin ofClostridium botulinum,”Vaccine14:1538-1544 (1996).
Dineen et al, Swiss Prot sequence Q8KHn9, Oct. 1, 2002.
Dolimbek and Alessi, “Protection against alpha-bungarotoxin poisoning by immunization with synthetic toxin peptides,”Mol. lmmunol. 33:681-689(1996).
Dolimbek et al., “Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response,ȁ
Allergan Inc.
Baylor College of Medicine
Condino Debra D.
German Joel B.
Mondesi Robert B
LandOfFree
BoNT/A peptides and methods of predicting and reducing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with BoNT/A peptides and methods of predicting and reducing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BoNT/A peptides and methods of predicting and reducing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4134077